Advertisement

Neuropsychological prediction of treatment response and outcome in schizophrenia

  • R. M. Bilder
  • J. A. Bates

Abstract

Despite decades of experience using antipsychotic medications, we still have a very limited capacity to predict who among our patients will benefit, how much they will benefit, and the extent to which they are likely to suffer disabling side effects from treatment. The contributions to this volume reflect increasing insight into a range of factors that may influence treatment response and outcome, but it is ironic that we can repeat the lament of Philip May and his colleagues in that the situation today has advanced little since 1964 (May 1966, May et al. 1976). Investigators continue to comment that the best predictor of antipsychotic treatment response is a prior history of response to the same treatment (May and Goldberg 1978, Awad 1989). In the era when only “typical” neuroleptic treatments were available, this lack of predictive power may have made less difference to clinicians, but the rapid development of new antipsychotic agents prompts a need to enhance our capacity to predict who will benefit, and who may be at increased risk from different treatments. One goal for current research is determining how neuropsychological (NP) methods may help both in the prediction and the definition of outcome. The key advantages of neuropsychology in these contexts include: (a) the possibility that NP methods may distinguish reliably between reversible state effects and more persistent trait effects; and (b) the possibility that NP methods may offer more valid indices of integrity or compromise within the specific functional brain systems that are the targets of antipsychotic drug treatments. To the extent that NP indices of specific neuropsychopharmacologic system functions can be validated, there are new opportunities to develop targeted treatment strategies, which could include rational selection of treatments based on NP profiles, and titration of ongoing treatments using changes in NP function as the key dependent measures.

Keywords

Reaction Time Measure Fluphenazine Decanoate Antipsychotic Drug Treatment Target Treatment Strategy Island Jewish Medical 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arndt S, Alliger RJ, Andreasen NC (1991) The distinction of positive and negative symptoms: the failure of a two-dimensional model. Br J Psychiatry 158:317–322.PubMedCrossRefGoogle Scholar
  2. Asarnow RF, MacCrimmon DJ (1982) Attention/Information processing, neuropsychological functioning, and thought disorder during the acute and partial recovery phase of schizophrenia: a longitudinal study. Psychiatry Res 7:309–319.PubMedCrossRefGoogle Scholar
  3. Awad AG (1989) Drug therapy in schizophrenia — Variability of outcome and prediction of response. Can J Psychiatry 34:711–720.PubMedGoogle Scholar
  4. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK (1985) Symptomatic and neuropsychological components of defect states. Schizophr Bull 11:409–418.PubMedGoogle Scholar
  5. Bilder RM, Lipschutz-Broch L, Reiter G, Geisler SH, Mayerhoff DI, Lieberman JA (1992a) Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr Bull 18:437–448.PubMedGoogle Scholar
  6. Bilder RM, Turkei E, Lipschutz-Broch L, Lieberman JA (1992b) Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 4:353–366.Google Scholar
  7. Cancro R, Sutton S, Kerr J, Sugerman A (1971) Reaction time and prognosis in acute schizophrenia. J Nerv Ment Dis 151:351–359.Google Scholar
  8. Jaeger J, Douglas E (1992) Neuropsychiatric rehabilitation for persistent mental illness. Psychiatr Q 63:71–94.PubMedCrossRefGoogle Scholar
  9. Kay SR, Singh MM (1979) Cognitive abnormality in schizophrenia: a dual-process model. Biol Psychiatry 14:155–176.PubMedGoogle Scholar
  10. Kern RS, Green MF, Satz P (1992) Neuropsychological predictors of skills training for chronic psychiatric patients. Psychiatry Res 43:223–230.PubMedCrossRefGoogle Scholar
  11. Liddle PF (1987) The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry 151:145–151.PubMedCrossRefGoogle Scholar
  12. Lieberman JA, Sobel SN (1993) Predictors of treatment response and course of schizophrenia. Curr Opin Psychiatry 6:63–69.CrossRefGoogle Scholar
  13. Lieberman JA (1993) Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 54[Suppl 3]:13–17.PubMedGoogle Scholar
  14. Marder SR, Asarnow RF, Van Putten T (1984) Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatry Res 13:41–49.PubMedCrossRefGoogle Scholar
  15. Marder SR, Asarnow RF, Van Putten (1988) Information processing and maintenance dose requirements in schizophrenia. Psychopharmacol Bull 24:247–250.PubMedGoogle Scholar
  16. May PRA (1966) Prediction in neuropsychopharmacology — a summary. In: Wittenborn JR, May PRA (eds) Prediction of response to pharmacotherapy. Charles C Thomas, Springfield Illinois, pp 201–215.Google Scholar
  17. May PRA, Van Putten T, Yale C, Potepan P, Jenden DJ, Fairchild MD, Goldstein MJ, Dixon WJ (1976) Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis 162:177–183.PubMedCrossRefGoogle Scholar
  18. May PRA, Goldberg SC (1978) Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1139–1153.Google Scholar
  19. Mueser KT, Bellack AS, Douglas MS, Wade JH (1991) Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology. Psychiatry Res 37:281–296.PubMedCrossRefGoogle Scholar
  20. Pogue-Geile MF, Harrow M (1983) The longitudinal study of negative symptoms in schizophrenia: psychomotor retardation. Annual Meeting of the American Psychological Association, Anaheim, CA, August 1983 (Abstract).Google Scholar
  21. Smith RC, Largen J, Vroulis G, Ravichandran GK (1992) Neuropsychological test scores and clinical response to neuroleptic drugs in schizophrenic patients. Compr Psychiatry 33:139–145.PubMedCrossRefGoogle Scholar
  22. Weaver LA, Brooks GW (1963) The use of psychomotor tests in predicting the potential of chronic schizophrenics. J Neuropsychiatry 5:170–180.Google Scholar
  23. Wykes T, Dunn G (1992) Cognitive deficit and the prediction of rehabilitation success in a chronic psychiatric group. Psychol Med 22:389–398.PubMedCrossRefGoogle Scholar
  24. Zahn TP, Carpenter WT (1978) Effects of short-term outcome and clinical improvement on reaction time in acute schizophrenia. J Psychiatr Res 14:59–68.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • R. M. Bilder
    • 1
  • J. A. Bates
    • 2
  1. 1.Hillside Hospital DivisionLong Island Jewish Medical CenterGlen OaksUSA
  2. 2.Long Island CampusAlbert Einstein College of MedicineUSA

Personalised recommendations